RE: "Excellence In Clinical Research Award"
Hey winer .......you on The Brewsky's already???........LOL!!!
These awards pretty much underlines the significance of the Positive E1-INT Data that the market so non-chalantly swept aside a while ago.
It is apparent that The E1-INT Data was Absolutely Outstanding and generated a lot of interest from different party's in ALL Gastrin(G1)(-INT) Based Research and in particular E1-INT!!
E1-INT will be going forward into Phasellb's with or without Novo. If they choose to not proceed another Co. will. The 100% nausea seen in the Phasella was necessary to find highest dosing parameters. A necessary evil.... if you will. You can bet your bottom dollar there will be a much much much lower incidence of nausea type adverse events in the next Phasellb because of that!!
GLA